Ecnoglutide

Ecnoglutide is a GLP-1 agonist being developed for the treatment of obesity and type 2 diabetes. In preclinical trials, "Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process" compared to other GLP-1 agonist lipopeptides.
A phase 3 trial published in 2025 showed 9-13% reduction in bodyweight versus placebo over a 48 week treatment, varying by ecnoglutide dose.
In January 2026, ecnoglutide injection is approved for marketing in China.